Message Font: Serif | Sans-Serif
No. of Recommendations: 0
RP shareholders are experiencing a transformation of their company from a diversified pharmaceuticals/chemicals/fibers to a purely pharmaceuticals holding. The acquisition gives RP the remaining ~50% of RPR that it didn't already own.

Management has outlined its plans, already being implemented, to concentrate on the higher margin pharmaceuticals business and, in the process, spin off its low margins chemicals and fibers business. The spin off will take place piece-meal, with a partial offering in the first half of '98. As these business segments improve, the remainder will be spun off at a higher price.

In two years time, RP will be entirely a pharmaceuticals firm, and a premier one at that. Consequently, shareholders can expect higher margins and returns on equity.
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.